{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:35:27Z","timestamp":1760056527591,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"British Microcirculation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ccl.2021.04.005","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T22:11:48Z","timestamp":1625782308000},"page":"435-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Atrial Fibrillation in Patients with Chronic Kidney Disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Agnieszka","family":"Kotalczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wern Yew","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher F.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirudh","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhiraj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ccl.2021.04.005_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib2","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.005_bib3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.005_bib4","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.005_bib5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvaa258","article-title":"Pathophysiology of atrial fibrillation and chronic kidney disease","volume":"117","author":"Ding","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ccl.2021.04.005_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2017.12.017","article-title":"Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation","volume":"198","author":"Fauchier","year":"2018","journal-title":"Am Heart J"},{"issue":"13","key":"10.1016\/j.ccl.2021.04.005_bib7","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2016.06.057","article-title":"Atrial fibrillation and thromboembolism in patients with chronic kidney disease","volume":"68","author":"Lau","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.005_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.005_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"Potpara","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.005_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000509567","article-title":"Increased incident ischemic stroke risk in advanced kidney disease: a large-scale real-world data study","volume":"51","author":"Maeda","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ccl.2021.04.005_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijcard.2020.08.068","article-title":"Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and chronic kidney disease in Asian Population, Data from the COOL-AF Thailand registry","volume":"323","author":"Chantrarat","year":"2020","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.005_bib12","first-page":"31","article-title":"Position paper on the safety\/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: consensus document of Societ\u00e0 Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle tera","volume":"34","author":"Grandone","year":"2020","journal-title":"J\u00a0Nephrol"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.005_bib13","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11739-019-02100-9","article-title":"Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease","volume":"14","author":"Godino","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.005_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/europace\/euz358","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.005_bib15","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.005_bib16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.005_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ahj.2009.06.031","article-title":"Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study","volume":"158","author":"Watanabe","year":"2009","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.005_bib18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.amjcard.2012.12.045","article-title":"Renal impairment in a \u201creal-life\u201d cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding)","volume":"111","author":"Rold\u00e1n","year":"2013","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib19","first-page":"282","article-title":"Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: an ancillary analysis from the BOREALIS trial","volume":"36","author":"Bai","year":"2020","journal-title":"J\u00a0Arrhythmia"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.005_bib20","doi-asserted-by":"crossref","first-page":"18055","DOI":"10.1038\/s41598-019-54528-w","article-title":"Fluctuating renal function and the risk of incident atrial fibrillation: a nationwide population-based study","volume":"9","author":"Kwon","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ccl.2021.04.005_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijcard.2018.11.098","article-title":"Comparison of atrial fibrillation in CKD and non-CKD populations: a cross-sectional analysis from the Kailuan study","volume":"277","author":"Guo","year":"2019","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.005_bib22","doi-asserted-by":"crossref","first-page":"e0230189","DOI":"10.1371\/journal.pone.0230189","article-title":"Association of atrial fibrillation and clinical outcomes in adults with chronic kidney disease: a propensity score-matched analysis","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.005_bib23","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2215\/CJN.10921015","article-title":"Atrial fibrillation and risk of ESRD in adults with CKD","volume":"11","author":"Bansal","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.005_bib24","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","article-title":"Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis","volume":"27","author":"Zimmerman","year":"2012","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.005_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ccl.2021.04.005_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fmed.2020.00054","article-title":"Stroke and bleeding risk assessments in patients with atrial fibrillation: concepts and controversies","volume":"7","author":"Ding","year":"2020","journal-title":"Front Med"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.005_bib27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/europace\/euv202","article-title":"Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making- A position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Socie","volume":"17","author":"Boriani","year":"2015","journal-title":"Europace"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.005_bib28","first-page":"62","article-title":"Understanding and managing atrial fibrillation in patients with kidney disease","volume":"7","author":"Khouri","year":"2015","journal-title":"J\u00a0Atr Fibrillation"},{"issue":"24","key":"10.1016\/j.ccl.2021.04.005_bib29","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"issue":"4 Suppl 3","key":"10.1016\/j.ccl.2021.04.005_bib30","first-page":"16","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.005_bib31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.005_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jce.13118","article-title":"Safety and clinical outcomes of catheter ablation of atrial fibrillation in patients with chronic kidney disease","volume":"28","author":"Ullal","year":"2017","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"6\u20137","key":"10.1016\/j.ccl.2021.04.005_bib33","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.acvd.2019.02.006","article-title":"Renal function and outcomes after catheter ablation of patients with atrial fibrillation: the Guangzhou atrial fibrillation ablation registry","volume":"112","author":"Deng","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.005_bib34","first-page":"3","article-title":"Impaired renal function is associated with recurrence after cryoballoon catheter ablation for paroxysmal atrial fibrillation: a potential effect of non-pulmonary vein foci","volume":"69","author":"Yanagisawa","year":"2017","journal-title":"J\u00a0Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.005_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5603\/CJ.a2013.0116","article-title":"Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation","volume":"21","author":"Li","year":"2014","journal-title":"Cardiol J"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.005_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ndt\/gft233","article-title":"Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients","volume":"29","author":"Hayashi","year":"2014","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.005_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41569-020-00459-3","article-title":"Stroke prevention strategies in high-risk patients with atrial fibrillation","volume":"18","author":"Kotalczyk","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.005_bib38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.mayocp.2017.05.023","article-title":"Guideline-adherent antithrombotic treatment Improves outcomes in patients with atrial fibrillation: Insights from the community-based darlington atrial fibrillation registry","volume":"92","author":"Mazurek","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.005_bib40","first-page":"933","article-title":"Patient outcomes using the European label for dabigatran: a post-hoc analysis from the RE-LY database","volume":"111","author":"Lip","year":"2014","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.005_bib41","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non\u2013vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Chan","year":"2020","journal-title":"Hear Rhythm"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.005_bib42","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"Borre","year":"2018","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.005_bib43","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.005_bib45","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1055\/s-0038-1651482","article-title":"Dynamic changes of CHA 2 DS 2 -VASc score and the risk of Ischaemic stroke in asian patients with atrial fibrillation: a nationwide cohort study","volume":"118","author":"Yoon","year":"2018","journal-title":"Thromb Haemost"},{"issue":"16","key":"10.1016\/j.ccl.2021.04.005_bib46","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.ccl.2021.04.005_bib47","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"B\u00f6hm","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.005_bib48","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1111\/bcp.14350","article-title":"Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: a multicentre cohort study","volume":"86","author":"Pastori","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.005_bib49","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH17-06-0416","article-title":"Relation of renal dysfunction to quality of anticoagulation control in patients with atrial fibrillation: the FANTASIIA registry","volume":"118","author":"Esteve-Pastor","year":"2018","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.005_bib51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21037\/cdt.2019.07.09","article-title":"Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III clinical trials","volume":"9","author":"Gu","year":"2019","journal-title":"Cardiovasc Diagn Ther"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.005_bib52","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","article-title":"Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation","volume":"20","author":"Chan","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.005_bib53","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1161\/STROKEAHA.117.017114","article-title":"Warfarin use in patients with atrial fibrillation undergoing hemodialysis: a nationwide population-based study","volume":"48","author":"Yoon","year":"2017","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/nep.13207","article-title":"Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation","volume":"24","author":"Tan","year":"2019","journal-title":"Nephrology"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.005_bib55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.005_bib56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2015.05.019","article-title":"Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation","volume":"66","author":"Shen","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"10.1016\/j.ccl.2021.04.005_bib57","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.005_bib58","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study","volume":"36","author":"Friberg","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.005_bib59","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ejh.13383","article-title":"Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis","volume":"104","author":"Miao","year":"2020","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.005_bib60","first-page":"1114","article-title":"2014 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.005_bib61","first-page":"345","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","journal-title":"J\u00a0Arrhythmia"},{"issue":"22","key":"10.1016\/j.ccl.2021.04.005_bib62","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.005_bib63","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.005_bib64","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.005_bib65","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.ccl.2021.04.005_bib66","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ccl.2021.04.005_bib67","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.005_bib68","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.005_bib69","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.005_bib71","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.amjcard.2019.10.033","article-title":"Safety and efficacy of direct oral anticoagulants versus warfarin in patients with chronic kidney disease and atrial fibrillation","volume":"125","author":"Makani","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2021.04.005_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.005_bib73","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.amjmed.2019.06.006","article-title":"Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease","volume":"132","author":"Chang","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.ccl.2021.04.005_bib74","series-title":"American heart association annual scientific sessions (AHA 2019), Philadelphia, PA","article-title":"RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF) on behalf of the RENAL-AF Investigators","author":"Pokorney","year":"2019"},{"issue":"18","key":"10.1016\/j.ccl.2021.04.005_bib75","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2021.04.005_bib76","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/europace\/euz258","article-title":"EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion-an update","volume":"22","author":"Glikson","year":"2020","journal-title":"Europace"},{"issue":"24","key":"10.1016\/j.ccl.2021.04.005_bib77","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis","volume":"65","author":"Holmes","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.005_bib78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00392-020-01638-5","article-title":"Left atrial appendage closure in patients with chronic kidney disease: results from the German multicentre LAARGE registry","volume":"110","author":"Fastner","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ccl.2021.04.005_bib79","first-page":"3","article-title":"Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis","volume":"1","author":"Genovesi","year":"2020","journal-title":"J\u00a0Nephrol"},{"issue":"19","key":"10.1016\/j.ccl.2021.04.005_bib80","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/heartjnl-2020-316977","article-title":"Atrial fibrillation and the prothrombotic state: revisiting Virchow\u2019s triad in 2020","volume":"106","author":"Ding","year":"2020","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.005_bib81","first-page":"1241","article-title":"Anticoagulation in patients with advanced chronic kidney disease: walking the fine line between benefit and harm","volume":"35","author":"Jegatheswaran","year":"2019","journal-title":"Can J Cardiol"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386512100028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386512100028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:54:51Z","timestamp":1760007291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386512100028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S073386512100028X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2021.04.005","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial Fibrillation in Patients with Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2021.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}